Management

REVA Medical's talented executive management team has extensive depth and breadth of experience working with start-up and development companies in the pharmaceutical, biotechnology and medical device fields.

• Robert Stockman

  Chairman and CEO

  Robert Stockman, the Company's co-founder, has served as its Chairman of the Board and director since 1999 and its Chief Executive Officer since August 2010. Mr. Stockman has also served as a director of HeartWare Limited and subsequently HeartWare International, Inc., a US medical device company listed on ASX and NASDAQ since December 2006 and has served on the board of Zeltiq Aesthetics, Inc., a medical technology company listed on NASDAQ, since July 2010. Mr. Stockman was appointed to the Board of Overseers for The Tuck School of Business at Dartmouth College in November 2011. Since 1999, Mr. Stockman has been the President and Chief Executive Officer of Group Outcome LLC, a US-based merchant banking firm which deploys its capital and that of its financial partners in private equity and venture capital investments in medical technology companies. Mr. Stockman also co-founded Centrimed, Inc., an internet-based software company that was acquired by Global Healthcare Exchange, LLC. He led the buyouts of Ioptex, an intraocular lens manufacturer, and two Johnson & Johnson divestitures, "A" Company Orthodontics, Inc. and Critikon Company, LLC, each of which was subsequently acquired. Prior to establishing Group Outcome LLC, Mr. Stockman spent 18 years with Johnston Associates, Inc. and Narragansett Capital Corporation, where he focused on venture capital investments and merger advisory work in the health care sector. Mr. Stockman holds a Bachelors Degree from Harvard College and a Master of Business Administration from The Amos Tuck School of Business at Dartmouth College.
  

• Robert Schultz PhD

  President and COO

  Robert Schultz, Ph.D. has served as our President and COO since 2003. His background comprises more than 30 years in pharmaceutical, medical device and combination products. Prior to joining REVA Medical, Dr. Schultz held positions of Vice President of Research and Development and Vice President of Technology Strategy and Licensing for Dura Pharmaceuticals, a specialty respiratory pharmaceutical and pulmonary drug-delivery company, and Research Specialist for 3M Pharmaceuticals, a diversified international technology company. He obtained his Ph.D. in Pharmaceutics and his BS degree in Pharmacy from the University of Minnesota.
  

• Katrina Thompson

  CFO and Corporate Secretary

  Katrina Thompson has served as our Chief Financial Officer and Corporate Secretary since 2003. Her experience encompasses over 30 years in accounting, finance, and corporate administration. Prior to joining REVA in 2003, Ms. Thompson held senior positions in the telecom, real estate development, commercial nursery and high tech industries. She spent the early part of her career with Price Water, a provider of tax, audit and advisory services. Ms. Thompson received her BS in Business Administration from San Diego State University.
  

• Jeffrey Anderson

  Vice President of Clinical and Regulatory Affairs

  Jeffrey Anderson has served as our Vice President of Clinical and Regulatory Affairs since February 2011, a position he previously held at REVA from 2004 to 2008. He has over 20 years of experience in the medical device industry, including his positions of Vice President of Clinical & Regulatory Affairs and Vice President of Research & Development for Neomend. Additionally, Mr. Anderson has held senior positions at Abbott Vascular, Jomed, CRS Clinical Research, and Medtronic. Mr. Anderson received his BS in Physics from California State University Fullerton.
  

• Joan Zeltinger PhD

  Vice President of Scientific Affairs

  Joan Zeltinger, Ph.D. has served as our Vice President of Scientific Affairs since June 2004 and has directed our biological and preclinical activities since 2000. Dr. Zeltinger has 20 years of industry research and business experience that includes numerous publications and patents. Dr. Zeltinger previously directed Advanced Tissue Sciences' bioresorbable coronary graft and tissue engineered heart valve programs and chaired ASTM standard development for combination medical products. She received a PhD in Biology from the University of South Carolina with post-doctoral work conducted at the University of Washington, School of Medicine, and has a BS in Biology from the University of North Dakota.
  

• Donald Brandom PhD

  Vice President of Product Development

  Donald Brandom, Ph.D. is our Vice President of Product Development. He has directed all biomaterials development activities since 2003 and the stent development program since 2010. In his over 20 years of industry experience, he has held technical, senior and executive management product development positions in the aerospace, microelectronics and medical device industries. Dr. Brandom earned his PhD in Materials Engineering Science at Virginia Tech and has a BS in Chemistry from the University of California, Davis.